Monday, May 6, 2013

Ruling thrills patients and boosts Indian generic drug makers By Betwa Sharma | May 6, 2013, 12:00 AM PDT

DELHI — In a widely reported judgment at home and abroad, India’s top court last month turned down a patent for a cancer drug costing $2,600 a month, in a huge victory for Indian generic drug makers who can now continue to sell it for $175 a month.
While Swiss drug maker Novartis said that the ruling discouraged innovation, it was hailed by legal and health experts as a balanced decision that set tough standards for innovation as well as protected consumers from being charged high prices for newer versions of drugs that did not have greater healing power than the older versions.
continue to read here

No comments: